{"id":9125,"date":"2021-03-18T15:18:29","date_gmt":"2021-03-18T14:18:29","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=9125"},"modified":"2021-05-20T10:27:17","modified_gmt":"2021-05-20T09:27:17","slug":"pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/","title":{"rendered":"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l’honneur dans le magazine CORDIS de la Commission Europ\u00e9enne"},"content":{"rendered":"\n

Article publi\u00e9 le 15 mars 2021 sur Zonebourse.com<\/a><\/p>\n\n\n\n

15\/03\/2021 | 17:46<\/a><\/a><\/a><\/p>\n\n\n\n

Regulatory News:<\/p>\n\n\n\n

Pherecydes Pharma <\/strong>(FR0011651694 – ALPHE) (Paris:ALPHE), soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans la phagoth\u00e9rapie de pr\u00e9cision destin\u00e9e \u00e0 traiter les infections bact\u00e9riennes r\u00e9sistantes aux antibiotiques et\/ou compliqu\u00e9es, annonce aujourd\u2019hui que son projet PhagoPROD financ\u00e9 en partie par la Commission Europ\u00e9enne fait l\u2019objet d\u2019une publication dans le magazine CORBIS consultable en cliquant sur ce lien<\/a>.<\/p>\n\n\n\n

CORBIS est le magazine de la Commission Europ\u00e9enne qui met en exergue les projets de recherche et d\u00e9veloppement les plus strat\u00e9giques financ\u00e9s par l\u2019Union Europ\u00e9enne (UE).<\/p>\n\n\n\n

PhagoPROD est un des pans constitutifs du d\u00e9veloppement de Pherecydes Pharma b\u00e9n\u00e9ficiant des financements Horizon 20\/20 qui permet \u00e0 la soci\u00e9t\u00e9 de mettre en place tous les proc\u00e9d\u00e9s de production n\u00e9cessaires \u00e0 la production de phages selon les Bonnes Pratiques de Production (BPF). Ces phages de haute qualit\u00e9 pharmaceutique sont n\u00e9cessaires au d\u00e9marrage des essais cliniques et \u00e0 leur mise \u00e0 disposition aupr\u00e8s du corps m\u00e9dical dans le cadre des Autorisations Temporaires d\u2019Utilisation (ATU). Ce projet financ\u00e9 pour un montant de 2,4 M\u20ac par l\u2019UE a \u00e9t\u00e9 initi\u00e9 fin 2018 et amend\u00e9 en 2020.<\/p>\n\n\n\n

Guy-Charles Fanneau de La Horie, Pr\u00e9sident du Directoire de Pherecydes Pharma<\/strong>, d\u00e9clare : \u00ab Nous sommes tr\u00e8s heureux d\u2019avoir \u00e9t\u00e9 s\u00e9lectionn\u00e9s par la Commission Europ\u00e9enne pour figurer dans ce num\u00e9ro de CORDIS. Au moment o\u00f9 la production de m\u00e9dicaments biologiques est devenue une priorit\u00e9 strat\u00e9gique, l\u2019UE nous soutient dans la mise en place des proc\u00e9d\u00e9s de fabrication de produits visant \u00e0 r\u00e9duire l\u2019impact du prochain tsunami dans le domaine de la sant\u00e9 que sont les infections bact\u00e9riennes r\u00e9sistantes aux antibiotiques et\/ou compliqu\u00e9es qui pourraient \u00eatre responsables de plus de 10 millions de morts par an \u00e0 horizon 2050 1<\/sup>. Gr\u00e2ce \u00e0 ce financement obtenu en 2018 et au r\u00e9seau de partenaires europ\u00e9ens que nous avons b\u00e2ti, nous savons produire des lots de phages BPF sur le territoire europ\u00e9en, ce qui nous ouvre d\u00e9sormais la voie du d\u00e9veloppement de la phagoth\u00e9rapie \u00e0 grande \u00e9chelle. \u00bb<\/em><\/p>\n\n\n\n

A propos de Pherecydes Pharma<\/strong><\/p>\n\n\n\n

Cr\u00e9\u00e9e en 2006, Pherecydes Pharma est une soci\u00e9t\u00e9 de biotechnologie qui d\u00e9veloppe des traitements contre les infections bact\u00e9riennes r\u00e9sistantes, responsables de nombreuses infections graves. La soci\u00e9t\u00e9 a mis au point une approche innovante, la phagoth\u00e9rapie de pr\u00e9cision, bas\u00e9e sur l\u2019utilisation de phages, virus naturels tueurs de bact\u00e9ries. <\/p>\n\n\n\n

Pherecydes Pharma d\u00e9veloppe un portefeuille de phages ciblant 3 bact\u00e9ries parmi les plus r\u00e9sistantes et dangereuses qui repr\u00e9sentent \u00e0 elles seules plus de deux tiers des infections nosocomiales r\u00e9sistantes : Staphylococcus aureus<\/em>, Escherichia coli <\/em>et Pseudomonas aeruginosa<\/em>. Le concept de phagoth\u00e9rapie de pr\u00e9cision a \u00e9t\u00e9 appliqu\u00e9 avec succ\u00e8s chez 22 patients dans le cadre de traitements compassionnels, sous la supervision de l\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM). Pherecydes Pharma, dont le si\u00e8ge social est \u00e0 Nantes, s’appuie sur une \u00e9quipe d\u2019une vingtaine d\u2019experts issus de l’industrie pharmaceutique, des biotechnologies et de la recherche acad\u00e9mique.<\/p>\n\n\n\n

Pour plus d\u2019informations, www.pherecydes-pharma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Article publi\u00e9 le 15 mars 2021 sur Zonebourse.com 15\/03\/2021 | 17:46 Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans la phagoth\u00e9rapie de pr\u00e9cision destin\u00e9e \u00e0 traiter les infections bact\u00e9riennes r\u00e9sistantes aux antibiotiques et\/ou compliqu\u00e9es, annonce aujourd\u2019hui que son projet PhagoPROD financ\u00e9 en partie par la Commission Europ\u00e9enne fait l\u2019objet d\u2019une publication […]<\/p>\n","protected":false},"author":139,"featured_media":9135,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"\nPherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l'honneur dans le magazine CORDIS de la Commission Europ\u00e9enne - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l'honneur dans le magazine CORDIS de la Commission Europ\u00e9enne - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-18T14:18:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-20T09:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"503\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l’honneur dans le magazine CORDIS de la Commission Europ\u00e9enne\",\"datePublished\":\"2021-03-18T14:18:29+00:00\",\"dateModified\":\"2021-05-20T09:27:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\"},\"wordCount\":572,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\",\"name\":\"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l'honneur dans le magazine CORDIS de la Commission Europ\u00e9enne - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg\",\"datePublished\":\"2021-03-18T14:18:29+00:00\",\"dateModified\":\"2021-05-20T09:27:17+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg\",\"width\":960,\"height\":503,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l’honneur dans le magazine CORDIS de la Commission Europ\u00e9enne\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l'honneur dans le magazine CORDIS de la Commission Europ\u00e9enne - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/","og_locale":"fr_FR","og_type":"article","og_title":"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l'honneur dans le magazine CORDIS de la Commission Europ\u00e9enne - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2021-03-18T14:18:29+00:00","article_modified_time":"2021-05-20T09:27:17+00:00","og_image":[{"width":960,"height":503,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l’honneur dans le magazine CORDIS de la Commission Europ\u00e9enne","datePublished":"2021-03-18T14:18:29+00:00","dateModified":"2021-05-20T09:27:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/"},"wordCount":572,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/","name":"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l'honneur dans le magazine CORDIS de la Commission Europ\u00e9enne - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg","datePublished":"2021-03-18T14:18:29+00:00","dateModified":"2021-05-20T09:27:17+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/03\/Bacteriophage.jpg","width":960,"height":503,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/pherecydes-pharma-le-projet-de-production-de-phages-phagoprod-de-pherecydes-pharma-a-lhonneur-dans-le-magazine-cordis-de-la-commission-europeenne\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Pherecydes Pharma : le projet de production de phages (PhagoPROD) de Pherecydes Pharma \u00e0 l’honneur dans le magazine CORDIS de la Commission Europ\u00e9enne"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-17 09:06:13","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/9125"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=9125"}],"version-history":[{"count":5,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/9125\/revisions"}],"predecessor-version":[{"id":9139,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/9125\/revisions\/9139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/9135"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=9125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=9125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=9125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}